Home › Compare › HAZAF vs ABBV
HAZAF yields 6.91% · ABBV yields 3.06%● Live data
📍 HAZAF pulled ahead of the other in Year 1
Combined, HAZAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HAZAF + ABBV for your $10,000?
Hazama Ando Corporation engages in the construction and construction-related business in Japan and internationally. The company offers civil engineering and building construction services, including surveys, measurements, planning, designing, executing, supervising, technical guidance contract, commissioning, and consulting services. Its projects include offices, production and distribution facilities, medical and welfare facilities, educational and research facilities, cultural and sports facilities, commercial and leisure facilities, traditional facilities, housing complexes, and other buildings; and dams, water/sewer systems, tunnels, roads and land reclamation, bridges, airports, and other public works, as well as renewal, urban civil engineering, civil engineering structure, offshore engineering, and other projects. The company also provides real estate transaction services; and owns and uses real properties and securities. In addition, it undertakes soil survey and purification works, such as the collection, handling, and disposal of waste, as well as related consulting services; and offers planning, designing, and consulting services related to area and urban development, environmental improvements, etc. Further, the company is involved in power generation; and electricity, thermal, and other energy supply activities. Additionally, it sells construction materials, machinery, and appliances; develops, licenses, and sells software; and provides building maintenance and security services. The company was formerly known as Hazama Corporation and changed its name to Hazama Ando Corporation in April 2013. Hazama Ando Corporation was founded in 1873 and is headquartered in Tokyo, Japan.
Full HAZAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.